Insmed Inc (INSM)vsPalvella Therapeutics, Inc (PVLA)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PVLA
Palvella Therapeutics, Inc
$120.39
+3.58%
HEALTHCARE · Cap: $1.71B
Smart Verdict
WallStSmart Research — data-driven comparison
PVLA leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PVLA
Avoid23
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PVLA
PVLA has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PVLA
The primary concerns for PVLA are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PVLA is a value play — different risk/reward profiles.
INSM is growing revenue faster at 1.5% — sustainability is the question.
PVLA generates stronger free cash flow (-8M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Palvella Therapeutics, Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Palvella Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases, particularly those resulting from specific gene mutations. The company's lead investigational product addresses pachyonychia congenita, targeting critical unmet medical needs within this specialized patient demographic. Leveraging a strong gene therapy foundation, Palvella is dedicated to expanding its pipeline with transformative solutions aimed at significantly improving patient quality of life. With a strategic emphasis on research and development, the company is poised to make a meaningful impact in the rare disease treatment arena.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?